Simple liquid biopsy enables targeted therapies in castration-resistant prostate cancer

By Howard Scher, MD,

Despite the recent development of novel hormonal therapies - such as enzalutamide and abiraterone - directed at the androgen receptor in the management of castration-resistant prostate cancer, a proportion of men have disease that progresses on these drugs. In this video Dr. Howard Scher explains how the formulation of a unique assay, performed by a simple “liquid biopsy” or blood test, is enabling a clearer understanding of the mechanisms underlying resistance to these drugs and will facilitate selection of more targeted therapies in many patients.

Further Reading

http://www.nejm.org/doi/full/10.1056/nejmoa1315815